TY - JOUR
T1 - Mesenchymal stem/stromal cells as adjuvant therapy in COVID-19-associated acute lung injury and cytokine storm
T2 - Importance of cell identification
AU - Pawitan, Jeanne Adiwinata
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Theoretically, mesenchymal stem cells (MSCs) are very promising as adjuvant therapy to alleviate coronavirus disease 2019 (COVID-19)-associated acute lung injury and cytokine storm. Several published studies, which used MSCs to alleviate COVID-19-associated acute lung injury and cytokine storm, reported promising results. However, the evidence came from a case report, case series, and clinical trials with a limited number of participants. Therefore, more studies are needed to get robust proof of MSC beneficial effects.
AB - Theoretically, mesenchymal stem cells (MSCs) are very promising as adjuvant therapy to alleviate coronavirus disease 2019 (COVID-19)-associated acute lung injury and cytokine storm. Several published studies, which used MSCs to alleviate COVID-19-associated acute lung injury and cytokine storm, reported promising results. However, the evidence came from a case report, case series, and clinical trials with a limited number of participants. Therefore, more studies are needed to get robust proof of MSC beneficial effects.
KW - Acute respiratory distress syndrome
KW - Covid-19
KW - Cytokine storm
KW - Mesenchymal stem cells
KW - Pneumonia
UR - http://www.scopus.com/inward/record.url?scp=85129454396&partnerID=8YFLogxK
U2 - 10.4252/wjsc.v14.i3.264
DO - 10.4252/wjsc.v14.i3.264
M3 - Article
AN - SCOPUS:85129454396
SN - 1948-0210
VL - 14
SP - 264
EP - 266
JO - World Journal of Stem Cells
JF - World Journal of Stem Cells
IS - 3
ER -